PR- Global Cardiovascular Pharmaceuticals Market.pptx

1
Global Cardiovascular Pharmaceuticals Market to
be Propelled by Growing Investment in Research
and Drug Development, and Increasing Prevalence
of Heart Failure by CAGR of 5 During 2023
2033 Kenneth Research published a report titled
Cardiovascular Pharmaceuticals Market Global
Demand Analysis Opportunity Outlook 2033 which
delivers detailed overview of the global
cardiovascular pharmaceuticals market in terms of
market segmentation by drug class, distribution
channel, indication and by region. Further, for
the in-depth analysis, the report encompasses the
industry growth indicators, restraints, supply
and demand risk, along with detailed discussion
on current and future market trends that are
associated with the growth of the market.
The global cardiovascular pharmaceuticals market
is expected to grow at 5 CAGR over the
forecast period, i.e., 2023-2033. The market is
segmented by indication into hypertension,
arrhythmia, coronary artery disease, and
hyperlipidemia. Out of these, the hypertension
segment is expected to hold the largest share
over the forecast period in the global
cardiovascular pharmaceuticals market. This can
be attributed to unhealthy lifestyle choices and
lack of exercise among the population.
2
The global cardiovascular pharmaceuticals market
is estimated to grow on the back of rising
health care costs. Rising demand for more
effective cardiovascular drugs followed by
growing investment in research and drug
development, rising hospitalization and number
of admissions in critical care units, increasing
prevalence of heart failure, and surge in
availability of reimbursement policies is further
anticipated to increase the growth of the global
cardiovascular pharmaceuticals market. For more in
formations_at_https//www.kennethresearch.com/report
- details/cardiovascular-pharmaceuticals-market/1
0080125 Geographically, the global cardiovascular
pharmaceuticals market is segmented into five
major regions including North America, Europe,
Asia Pacific, Latin America and Middle East
Africa region. Out of them, the market in the
North America region is projected to hold the
largest market share by the end of 2033. This can
be attributed to the rise in stress, anxiety,
and obesity which is leading to diabetes and
heart disease as well as atrial fibrillation,
coronary artery disease, and strokes. The
research is global in nature and covers detailed
analysis on the market in North America (U.S.,
Canada), Europe (U.K., Germany, France, Italy,
Spain, Hungary, Belgium, Netherlands
Luxembourg, NORDIC Finland, Sweden, Norway,
Denmark, Poland, Turkey, Russia, Rest of
Europe), Latin America (Brazil, Mexico,
Argentina, Rest of Latin America), Asia-Pacific
(China, India, Japan, South Korea, Indonesia,
Singapore, Malaysia, Australia, New Zealand,
Rest of Asia-Pacific), Middle East and Africa
(Israel, GCC Saudi Arabia, UAE, Bahrain,
Kuwait, Qatar, Oman, North Africa, South Africa,
Rest of Middle East and Africa). In addition,
analysis comprising market size, Y-O-Y growth
opportunity analysis, market players competitive
study, investment opportunities, demand for
future outlook etc. has also been covered and
displayed in the research report. Increasing
Prevalence of Heart Failure to Boost the Market
Growth
3
Heart failure is a common complication of
cardiovascular disorders. Resulting from poor
lifestyle decisions, such as eating a lot of
salt, smoking, abusing alcohol or drugs, or not
taking preventative medications as
prescribed Furthermore, heart failure is becoming
more common, with an estimated 27 million people
suffering from the disease worldwide. However,
adverse effects of heart medication, expiration
of several medications patents, and high cost of
cardiovascular drugs are expected to operate as
key restraint to the growth of global
cardiovascular pharmaceuticals market over the
forecast period. This report also provides the
existing competitive scenario of some of the key
players of the global cardiovascular
pharmaceuticals market which includes company
profiling of Bristol-Myers Squibb Company, Bayer
AG, Pfizer Inc., Janssen Pharmaceuticals, Inc.,
Novartis AG, Merck Co., AstraZeneca plc, Sanofi
S.A., Gilead Sciences, Inc., F. Hoffmann-La
Roche, and others. The profiling enfolds key
information of the companies which encompasses
business overview, products and services, key
financials and recent news and developments. On
the whole, the report depicts detailed overview
of the global cardiovascular pharmaceuticals
market that will help industry consultants,
equipment manufacturers, existing players
searching for expansion opportunities, new
players searching possibilities and other
stakeholders to align their market centric
strategies according to the ongoing and expected
trends in the future. Request Report Sample_at_
https//www.kennethresearch.com/sample-request-
10080125 Kenneth Research is a leading service
provider for strategic market research and
consulting. We aim to provide unbiased,
unparalleled market insights and industry
analysis to help industries, conglomerates and
executives to take wise decisions for their
future marketing strategy, expansion and
investment etc. We believe every business can
expand to its new horizon, provided a right
guidance at a right time is available through
strategic minds. Our out of box thinking helps
our clients to take wise decision in order to
avoid future uncertainties.
4
Contact for more Info AJ Daniel Email
sales_at_kennethresearch.com U.S. Phone [phone]
0609